Immunotherapy before lung surgery shows promise in early trial

NCT ID NCT02259621

Ongoing Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested giving the immunotherapy drugs nivolumab (with or without ipilimumab) before surgery to people with a type of lung cancer called non-small-cell lung cancer. The goal was to see if this approach is safe and helps shrink tumors before removal. 39 participants were enrolled, and researchers measured side effects and how much tumor remained after surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Johnathan Spicer

Montreal, Quebec, H4 3J1, Canada
Johns Hopkins at Bayview Medical Center

Baltimore, Maryland, 21224, United States
Memorial Sloan Kettering

New York, New York, 10065, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21287, United States
Swedish Cancer Insitute

Edmonds, Washington, 98026, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.